genzyme
(6)
Bryan Ennis and the cost of leaving a feature switched off
From regulatory systems at Genzyme to customer success at Veeva, Bryan Ennis has followed the work that piles up behind a software release. At Sware, the co-founder and former CEO is turning that experience towards validation, quality and the adoption of AI.
Alan Walts Has Spent Four Decades Turning Chemistry Into Companies
The Aleta Biotherapeutics CEO built his career in the quiet machinery of biotech: translating science, assembling teams, making deals, and turning one mentor’s habit of connecting people into an institution.
The quiet engineer keeping Takeda's medicine flowing
He does not develop the drug or run the ads. He makes sure the thing gets made, on spec, on time, batch after batch - across a network of factories Takeda does not own.
Chris McNulty
Chris McNulty is the interim CEO of Ring Therapeutics, a Cambridge, Massachusetts biotech developing genetic medicines that use commensal anelloviruses as delivery vectors. An MIT-trained engineer with a Harvard MBA, he joined Ring in May 2023 as Chief Financial Officer and Head of Corporate Strategy and stepped up to lead the company in December 2024. Over more than 15 years in pharma and biotech finance, he has closed financing transactions worth more than $300 million across companies including VBI Vaccines, InVivo Therapeutics, Repligen, and Genzyme.
Blaine McKee
Blaine McKee is the president and CEO of Walden Biosciences, a Cambridge, Massachusetts biotech building first-in-class medicines that go after the kidney itself instead of just slowing the road to dialysis. A chemist turned dealmaker turned operator, he launched Walden with a $51 million Series A in 2020 and now steers two clinical-stage programs: WAL0921, an anti-suPAR antibody, and WAL0623, a small-molecule dynamin stabilizer. Before Walden he spent 15 years at Genzyme and held top corporate-development roles at Shire and ImmunoGen, pairing an MIT organic-chemistry PhD with an MIT Sloan finance MBA.
Timothy Noyes
Timothy Noyes is the President and CEO of Newleos Therapeutics, a Boston clinical-stage biotech that raised an oversubscribed $93.5M Series A to revive four neuropsychiatric compounds shelved by Roche. A Harvard-trained operator with three decades in biopharma, he has taken Proteon and Aerovate public, launched Renagel at GelTex/Genzyme, and built teams that carry molecules from bench to late-stage trials.